LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 244

Search options

  1. Article ; Online: Reconciling Mouse and Human Immunology at the Altar of Genetics.

    Gros, Philippe / Casanova, Jean-Laurent

    Annual review of immunology

    2022  Volume 41, Page(s) 39–71

    Abstract: Immunity to infection has been extensively studied in humans and mice bearing naturally occurring or experimentally introduced germline mutations. Mouse studies are sometimes neglected by human immunologists, on the basis that mice are not humans and the ...

    Abstract Immunity to infection has been extensively studied in humans and mice bearing naturally occurring or experimentally introduced germline mutations. Mouse studies are sometimes neglected by human immunologists, on the basis that mice are not humans and the infections studied are experimental and not natural. Conversely, human studies are sometimes neglected by mouse immunologists, on the basis of the uncontrolled conditions of study and small numbers of patients. However, both sides would agree that the infectious phenotypes of patients with inborn errors of immunity often differ from those of the corresponding mutant mice. Why is that? We argue that this important question is best addressed by revisiting and reinterpreting the findings of both mouse and human studies from a genetic perspective. Greater caution is required for reverse-genetics studies than for forward-genetics studies, but genetic analysis is sufficiently strong to define the studies likely to stand the test of time. Genetically robust mouse and human studies can provide invaluable complementary insights into the mechanisms of immunity to infection common and specific to these two species.
    MeSH term(s) Animals ; Humans ; Mice ; Phenotype ; Immunity/genetics ; Immune System Diseases/genetics
    Language English
    Publishing date 2022-12-16
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 604953-9
    ISSN 1545-3278 ; 0732-0582
    ISSN (online) 1545-3278
    ISSN 0732-0582
    DOI 10.1146/annurev-immunol-101721-065201
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness.

    Ursino, Chiara / Mouric, Cécile / Gros, Laurent / Bonnefoy, Nathalie / Faget, Julien

    Frontiers in immunology

    2023  Volume 14, Page(s) 1170321

    Abstract: Immune checkpoint blockade represents the latest revolution in cancer treatment by substantially increasing patients' lifetime and quality of life in multiple neoplastic pathologies. However, this new avenue of cancer management appeared extremely ... ...

    Abstract Immune checkpoint blockade represents the latest revolution in cancer treatment by substantially increasing patients' lifetime and quality of life in multiple neoplastic pathologies. However, this new avenue of cancer management appeared extremely beneficial in a minority of cancer types and the sub-population of patients that would benefit from such therapies remain difficult to predict. In this review of the literature, we have summarized important knowledge linking cancer cell characteristics with the response to immunotherapy. Mostly focused on lung cancer, our objective was to illustrate how cancer cell diversity inside a well-defined pathology might explain sensitivity and refractoriness to immunotherapies. We first discuss how genomic instability, epigenetics and innate immune signaling could explain differences in the response to immune checkpoint blockers. Then, in a second part we detailed important notions suggesting that altered cancer cell metabolism, specific oncogenic signaling, tumor suppressor loss as well as tight control of the cGAS/STING pathway in the cancer cells can be associated with resistance to immune checkpoint blockade. At the end, we discussed recent evidences that could suggest that immune checkpoint blockade as first line therapy might shape the cancer cell clones diversity and give rise to the appearance of novel resistance mechanisms.
    MeSH term(s) Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Quality of Life ; Lung Neoplasms ; Immunotherapy ; Chromogranin A
    Chemical Substances Immune Checkpoint Inhibitors ; Chromogranin A
    Language English
    Publishing date 2023-04-26
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1170321
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Les anticorps monoclonaux anti-tumoraux - Nouvelles perspectives pour générer une réponse immunitaire protectrice et durable.

    Deligne, Claire / Gros, Laurent

    Medecine sciences : M/S

    2020  Volume 35, Issue 12, Page(s) 982–989

    Abstract: Tumor-targeting monoclonal antibodies (mAbs) are now widely used for the treatment of cancer patients and their numbers are constantly increasing. Over the past ten years, numerous studies have demonstrated that the anti-tumor role of these antibodies ... ...

    Title translation Anti-tumor monoclonal antibodies: new insights to elicit a long-term immune response.
    Abstract Tumor-targeting monoclonal antibodies (mAbs) are now widely used for the treatment of cancer patients and their numbers are constantly increasing. Over the past ten years, numerous studies have demonstrated that the anti-tumor role of these antibodies far exceeds that of passive therapies as it was initially described, with the possibility of recruiting innate immune cells to promote activation of the early stages of immune response and to generate a long-term protective anti-tumor memory immune response. Understanding these mechanisms has recently led to the clinical development of a new generation of anti-tumor antibodies modified to increase their ability to interact with immune cells. Finally, the first preclinical and clinical studies have recently demonstrated the interest of developing therapeutic combinations combining anti-tumor mAbs with immune-, chemo- or radiotherapy, to reinforce their immunomodulatory potential and ensure effective and durable anti-tumor protection.
    MeSH term(s) Animals ; Antibodies, Monoclonal/therapeutic use ; Humans ; Immunotherapy/methods ; Immunotherapy/standards ; Molecular Targeted Therapy/methods ; Neoplasms/immunology ; Neoplasms/therapy ; Remission Induction ; Time Factors
    Chemical Substances Antibodies, Monoclonal
    Language French
    Publishing date 2020-01-06
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 632733-3
    ISSN 1958-5381 ; 0767-0974
    ISSN (online) 1958-5381
    ISSN 0767-0974
    DOI 10.1051/medsci/2019194
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: IV Versus Myelography Computed Tomography for Thoracolumbar Intervertebral Disc Extrusion Surgical Planning in French Bulldogs.

    Signoret, Marion / Gros, Lucille / Musso, Clément / Hahn, Harriet / Le Boedec, Kévin / Cauzinille, Laurent

    Journal of the American Animal Hospital Association

    2023  Volume 59, Issue 5, Page(s) 207–213

    Abstract: Accurate diagnostic imaging is required for surgical planning of acute thoracolumbar intervertebral disc extrusion. However, data comparing the accuracy of conventional IV contrast-injected computed tomography (CT) and myelography CT for hemilaminectomy ... ...

    Abstract Accurate diagnostic imaging is required for surgical planning of acute thoracolumbar intervertebral disc extrusion. However, data comparing the accuracy of conventional IV contrast-injected computed tomography (CT) and myelography CT for hemilaminectomy localization and size assessment are sparse. In this study, IV contrast-injected CT and myelography CT were performed in 48 French bulldogs presenting with acute disc herniation and compared with postsurgical CT. CT images were evaluated by three raters. IV contrast-injected CT erroneously identified the compressive lesion site significantly more often than myelography CT. The length of the compressive lesion was significantly higher using myelography CT compared with conventional CT, but this did not lead to relevant consequences on the surgical opening site length. Myelography CT should therefore be recommended when thoracolumbar disc disease is suspected and multiple compressive lesions are visualized on IV-injected CT in French bulldogs.
    MeSH term(s) Animals ; Dogs ; Intervertebral Disc Displacement/diagnostic imaging ; Intervertebral Disc Displacement/surgery ; Intervertebral Disc Displacement/veterinary ; Myelography/veterinary ; Tomography, X-Ray Computed/veterinary ; Laminectomy/veterinary ; Intervertebral Disc ; Dog Diseases/diagnostic imaging ; Dog Diseases/surgery
    Language English
    Publishing date 2023-09-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 410383-x
    ISSN 1547-3317 ; 1062-8266 ; 0587-2871
    ISSN (online) 1547-3317
    ISSN 1062-8266 ; 0587-2871
    DOI 10.5326/JAAHA-MS-7318
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Persistent post-COVID-19 dysosmia: Practices survey of members of the French National Union of Otorhinolaryngology-Head and Neck Surgery Specialists. CROSS analysis.

    Vandersteen, Clair / Dubrulle, Claire / Manera, Valeria / Castillo, Laurent / Payne, Magali / Gros, Auriane

    European annals of otorhinolaryngology, head and neck diseases

    2023  Volume 140, Issue 4, Page(s) 159–163

    Abstract: Introduction: Persistent dysosmia more than 3 months after SARS-CoV-2 disease (COVID-19) is considered as long-COVID olfactory disease (LCOD). The primary objective of this study was to evaluate the diagnostic and therapeutic management of LCOD in the ... ...

    Abstract Introduction: Persistent dysosmia more than 3 months after SARS-CoV-2 disease (COVID-19) is considered as long-COVID olfactory disease (LCOD). The primary objective of this study was to evaluate the diagnostic and therapeutic management of LCOD in the daily clinical practice of members of the National Union of Otorhinolaryngology-Head and Neck Surgery Specialists (Syndicat national des médecins spécialisés en ORL et chirurgie cervico-faciale) (SNORL). The secondary objective was to identify factors influencing management within the descriptive survey data.
    Materials and methods: A questionnaire was designed (GoogleForm®) and e-mailed to all 715 SNORL members in January 2022.
    Results: The response rate was 7.4% (n=53/715). In total, 94.3% of respondents (n=50) had managed LCOD cases, and 56% (n=28) used psychophysical olfactory tests. Specific olfactory medical therapy involved local corticosteroid nasal sprays in 49.1% of cases (n=26) and oral corticosteroids in 32.1% (n=17). Olfactory self-training was prescribed by 81.1% of respondents, with associated speech pathologist therapy in 15.1% (n=8) of cases. No predictive factors for specific management were identified.
    Conclusion: Olfactometry is currently under-applied. Consistent with guidelines, non-drug therapy (olfactory training) is the first-line treatment for LCOD.
    MeSH term(s) Humans ; COVID-19 ; Post-Acute COVID-19 Syndrome ; SARS-CoV-2 ; Olfaction Disorders/etiology ; Olfaction Disorders/therapy ; Olfaction Disorders/diagnosis ; Otolaryngology ; Adrenal Cortex Hormones/therapeutic use ; Surveys and Questionnaires
    Chemical Substances Adrenal Cortex Hormones
    Language English
    Publishing date 2023-04-07
    Publishing country France
    Document type Journal Article
    ZDB-ID 2558008-5
    ISSN 1879-730X ; 1879-7296
    ISSN (online) 1879-730X
    ISSN 1879-7296
    DOI 10.1016/j.anorl.2023.04.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures.

    Larbouret, Christel / Gros, Laurent / Pèlegrin, André / Chardès, Thierry

    Cancers

    2021  Volume 13, Issue 18

    Abstract: Monoclonal antibodies have revolutionized the treatment of many diseases, but their clinical efficacy remains limited in some other cases. Pre-clinical and clinical trials have shown that combinations of antibodies that bind to the same target (homo- ... ...

    Abstract Monoclonal antibodies have revolutionized the treatment of many diseases, but their clinical efficacy remains limited in some other cases. Pre-clinical and clinical trials have shown that combinations of antibodies that bind to the same target (homo-combinations) or to different targets (hetero-combinations) to mimic the polyclonal humoral immune response improve their therapeutic effects in cancer. The approval of the trastuzumab/pertuzumab combination for breast cancer and then of the ipilimumab/nivolumab combination for melanoma opened the way to novel antibody combinations or oligoclonal antibody mixtures as more effective biologics for cancer management. We found more than 300 phase II/III clinical trials on antibody combinations, with/without chemotherapy, radiotherapy, small molecules or vaccines, in the ClinicalTrials.gov database. Such combinations enhance the biological responses and bypass the resistance mechanisms observed with antibody monotherapy. Usually, such antibody combinations are administered sequentially as separate formulations. Combined formulations have also been developed in which separately produced antibodies are mixed before administration or are produced simultaneously in a single cell line or a single batch of different cell lines as a polyclonal master cell bank. The regulation, toxicity and injection sequence of these oligoclonal antibody mixtures still need to be addressed in order to optimize their delivery and their therapeutic effects.
    Language English
    Publishing date 2021-09-15
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13184620
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Spinal epidural and synovial lipomatosis in a 3-year-old Eurasian dog receiving sustained steroid therapy.

    Signoret, Marion / Gros, Lucile / Dumont, Renaud / Dally, Claire / Le Boedec, Kevin / Cauzinille, Laurent

    Veterinary medicine and science

    2022  Volume 8, Issue 4, Page(s) 1373–1377

    Abstract: This report describes a spinal cord epidural and synovial lipomatosis in a 3-year-old neutered male Eurasian dog. This dog presented for ambulatory paraparesis and was previously treated with immunosuppressive dosages of prednisolone for 2 years. ... ...

    Abstract This report describes a spinal cord epidural and synovial lipomatosis in a 3-year-old neutered male Eurasian dog. This dog presented for ambulatory paraparesis and was previously treated with immunosuppressive dosages of prednisolone for 2 years. Computed tomography (CT) myelography and magnetic resonnance imaging (MRI) images identified dorsal compression of the thoraco-lumbar spinal cord by hypertrophic epidural fat. Histological examination identified extensive well-differentiated mature adipose tissue in the subepithelial area of the tarsal synovium. Prednisolone is a reported predisposing factor in humans with lipomatosis.
    MeSH term(s) Animals ; Dog Diseases/diagnostic imaging ; Dog Diseases/drug therapy ; Dog Diseases/pathology ; Dogs ; Epidural Space/pathology ; Humans ; Lipomatosis/diagnostic imaging ; Lipomatosis/veterinary ; Male ; Myelography/veterinary ; Prednisolone/therapeutic use ; Steroids
    Chemical Substances Steroids ; Prednisolone (9PHQ9Y1OLM)
    Language English
    Publishing date 2022-06-22
    Publishing country England
    Document type Case Reports
    ZDB-ID 2819409-3
    ISSN 2053-1095 ; 2053-1095
    ISSN (online) 2053-1095
    ISSN 2053-1095
    DOI 10.1002/vms3.842
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.

    Desroys du Roure, Pénélope / Lajoie, Laurie / Mallavialle, Aude / Alcaraz, Lindsay B / Mansouri, Hanane / Fenou, Lise / Garambois, Véronique / Rubio, Lucie / David, Timothée / Coenon, Loïs / Boissière-Michot, Florence / Chateau, Marie-Christine / Ngo, Giang / Jarlier, Marta / Villalba, Martin / Martineau, Pierre / Laurent-Matha, Valérie / Roger, Pascal / Guiu, Séverine /
    Chardès, Thierry / Gros, Laurent / Liaudet-Coopman, Emmanuelle

    Journal for immunotherapy of cancer

    2024  Volume 12, Issue 1

    Abstract: Introduction: Triple-negative breast cancer (TNBC) prognosis is poor. Immunotherapies to enhance the antibody-induced natural killer (NK) cell antitumor activity are emerging for TNBC that is frequently immunogenic. The aspartic protease cathepsin D ( ... ...

    Abstract Introduction: Triple-negative breast cancer (TNBC) prognosis is poor. Immunotherapies to enhance the antibody-induced natural killer (NK) cell antitumor activity are emerging for TNBC that is frequently immunogenic. The aspartic protease cathepsin D (cath-D), a tumor cell-associated extracellular protein with protumor activity and a poor prognosis marker in TNBC, is a prime target for antibody-based therapy to induce NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). This study investigated whether Fc-engineered anti-cath-D antibodies trigger ADCC, their impact on antitumor efficacy and tumor-infiltrating NK cells, and their relevance for combinatory therapy in TNBC.
    Methods: Cath-D expression and localization in TNBC samples were evaluated by western blotting, immunofluorescence, and immunohistochemistry. The binding of human anti-cath-D F1M1 and Fc-engineered antibody variants, which enhance (F1M1-Fc
    Results: Cath-D expression on the TNBC cell surface could be exploited to induce ADCC. F1M1 Fc-variants recognized human and mouse cath-D. F1M1-Fc
    Conclusions: F1M1-Fc
    MeSH term(s) Humans ; Animals ; Mice ; Triple Negative Breast Neoplasms/pathology ; Paclitaxel/pharmacology ; Paclitaxel/therapeutic use ; Cathepsin D ; Mice, Nude ; Cell Line, Tumor ; Antibody-Dependent Cell Cytotoxicity ; Antineoplastic Agents/therapeutic use ; Killer Cells, Natural ; Immunoglobulin Fc Fragments ; Benzamides ; Nitriles ; Phenylthiohydantoin
    Chemical Substances enzalutamide (93T0T9GKNU) ; Paclitaxel (P88XT4IS4D) ; Cathepsin D (EC 3.4.23.5) ; Antineoplastic Agents ; Immunoglobulin Fc Fragments ; Benzamides ; Nitriles ; Phenylthiohydantoin (2010-15-3)
    Language English
    Publishing date 2024-01-30
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2023-007135
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: A Gradient-Descent Optimization of CO

    Abdallah, Charbel / Lauvaux, Thomas / Lian, Jinghui / Bréon, François-Marie / Ramonet, Michel / Laurent, Olivier / Ciais, Philippe / Denier van der Gon, Hugo A C / Dellaert, Stijn / Perrussel, Olivier / Baudic, Alexia / Utard, Hervé / Gros, Valérie

    Environmental science & technology

    2023  Volume 58, Issue 1, Page(s) 302–314

    Abstract: Urban greenhouse gas emissions monitoring is essential to assessing the impact of climate mitigation actions. Using atmospheric continuous measurements of air quality and carbon dioxide ( ... ...

    Abstract Urban greenhouse gas emissions monitoring is essential to assessing the impact of climate mitigation actions. Using atmospheric continuous measurements of air quality and carbon dioxide (CO
    MeSH term(s) Humans ; Air Pollutants/analysis ; Carbon Dioxide/analysis ; SARS-CoV-2 ; Bayes Theorem ; COVID-19 ; Communicable Disease Control ; Greenhouse Gases/analysis
    Chemical Substances Air Pollutants ; Carbon Dioxide (142M471B3J) ; Greenhouse Gases
    Language English
    Publishing date 2023-12-19
    Publishing country United States
    Document type Journal Article
    ISSN 1520-5851
    ISSN (online) 1520-5851
    DOI 10.1021/acs.est.3c00566
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Asteroid Hyalosis: A Mimicker of Vitreous Hemorrhage on Point of Care Ultrasound: A Case Report.

    Gros, Eniola C / Mccafferty, Lauren R

    POCUS journal

    2023  Volume 8, Issue 2, Page(s) 113–115

    Abstract: Ocular point of care ultrasound (POCUS) can help make timely recognition of multiple emergent ocular conditions and differentiate these from more benign conditions. While asteroid hyalosis (AH) is benign, it can easily mimic the more potentially serious ... ...

    Abstract Ocular point of care ultrasound (POCUS) can help make timely recognition of multiple emergent ocular conditions and differentiate these from more benign conditions. While asteroid hyalosis (AH) is benign, it can easily mimic the more potentially serious vitreous hemorrhage on ocular POCUS, as both consist of numerous echogenic opacities within the vitreous with a classic "washing machine" appearance with eye movement. However, asteroid hyalosis particles tend to be more discrete, hyperechoic, scintillating, and seen throughout the vitreous. Knowledge of this mimic and ability to recognize the subtle sonographic differences can help differentiate these disease processes, which can influence management and potentially disposition.
    Language English
    Publishing date 2023-11-27
    Publishing country Canada
    Document type Case Reports
    ISSN 2369-8543
    ISSN (online) 2369-8543
    DOI 10.24908/pocus.v8i2.16391
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top